Free Trial
NASDAQ:IPSC

Century Therapeutics Q1 2025 Earnings Report

Century Therapeutics logo
$0.63 +0.07 (+12.61%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Century Therapeutics EPS Results

Actual EPS
$0.89
Consensus EPS
-$0.31
Beat/Miss
Beat by +$1.20
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
$109.16 million
Expected Revenue
$45.52 million
Beat/Miss
Beat by +$63.64 million
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Century Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Century Therapeutics Earnings Headlines

HC Wainwright Issues Positive Estimate for IPSC Earnings
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Q1 Earnings Estimate for IPSC Issued By HC Wainwright
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

View Century Therapeutics Profile

More Earnings Resources from MarketBeat